



The binding characteristics and orientation of a novel radioligand with distinct properties at 5-HT₃A and 5-HT₃AB receptors



Andrew J. Thompson^b, Mark H.P. Verheij^a, Joost Verbeek^c, Albert D. Windhorst^c, Iwan J.P. de Esch^a, Sarah C.R. Lummis^{b,*}

^a Amsterdam Institute for Molecules Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Faculty of Sciences, VU University Amsterdam, Amsterdam, The Netherlands

^b Department of Biochemistry, University of Cambridge, Cambridge, UK

^c VU University Medical Center, Dept Radiology & Nuclear Medicine, Amsterdam, The Netherlands

ARTICLE INFO

Article history:

Received 4 June 2014

Received in revised form

22 July 2014

Accepted 9 August 2014

Available online 28 August 2014

Keywords:

Antagonist

Cys-loop

Ion channel

Radioligand

5-HT₃

Agonist

ABSTRACT

VUF10166 (2-chloro-3-(4-methyl piperazin-1-yl)quinoxaline) is a ligand that binds with high affinity to 5-HT₃ receptors. Here we synthesise [³H]VUF10166 and characterise its binding properties at 5-HT₃A and 5-HT₃AB receptors. At 5-HT₃A receptors [³H]VUF10166 displayed saturable binding with a K_d of 0.18 nM. Kinetic measurements gave monophasic association ($6.25 \times 10^7 \text{ M}^{-1} \text{ min}^{-1}$) and dissociation (0.01 min^{-1}) rates that yielded a similar K_d value (0.16 nM). At 5-HT₃AB receptors two association (6.15×10^{-7} , $7.23 \text{ M}^{-1} \text{ min}^{-1}$) and dissociation (0.024 , 0.162 min^{-1}) rates were seen, yielding K_d values (0.38 nM and 22 nM) that were consistent with values obtained in saturation ($K_d = 0.74 \text{ nM}$) and competition ($K_i = 37 \text{ nM}$) binding experiments respectively. At both receptor types, specific binding was inhibited by classical 5-HT₃ receptor-selective orthosteric ligands (5-HT, allosestron, *d*-tubocurarine, granisetron, *m*CPBG, MDL72222, quipazine), but not by non-competitive antagonists (bilobalide, ginkgolide B, picrotoxin) or competitive ligands of other Cys-loop receptors (ACh, bicuculline, glycine, gabazine). To explore VUF10166 ligand–receptor interactions we used *in silico* modelling and docking, and tested the predictions using site directed mutagenesis. The data suggest that VUF10166 adopts a similar orientation to 5-HT₃ receptor agonists bound in AChBP (varenicline) and 5HTBP (5-HT) crystal structures.

© 2014 Published by Elsevier Ltd.

1. Introduction

5-HT₃ receptors are transmembrane ligand-gated ion-channels that are responsible for fast synaptic neurotransmission in the central and peripheral nervous systems. They are composed of five subunits, each of which contains an extracellular, a transmembrane and an intracellular domain (Thompson et al., 2008a; Miller and Smart, 2012). *In vivo* 5-HT₃ receptor activation can result in nausea and vomiting, and for over three decades competitive antagonists of these receptors have been used to alleviate these symptoms arising from cancer therapy and general anaesthetics. There is also a limited use of antagonists for treating irritable bowel

syndrome and pre-clinical interest in the use of partial agonists for the same disorder (Thompson and Lummis, 2007; Walstab et al., 2010; Thompson, 2013).

There are currently five 5-HT₃ receptor subunits (5-HT3A–5-HT3E), with further complexity arising from splice variants and species differences (Walstab et al., 2010). 5-HT3A subunits can form homomeric receptors, but the subunits 5-HT3B–5-HT3E must combine with 5-HT3A subunits to function. The functional properties of these receptor subtypes have been reported by several groups, but to date only the pharmacologies of 5-HT3A and 5-HT3AB receptors have been studied in detail (Holbrook et al., 2009; Walstab et al., 2010; Thompson et al., 2013; Thompson and Lummis, 2013). Until recently only pore-blocking antagonists were known to have different properties at 5-HT3A and 5-HT3AB receptors, and these differences could be attributed to the varying pore-lining amino acids of the 5-HT3A and 5-HT3B subunits (Thompson and Lummis, 2013). However, the utility of these compounds is limited as they tend to be of low affinity (μM range)

Abbreviations: 5-HT, 5-hydroxytryptamine; nACh, nicotinic acetylcholine; GABA, gamma-aminobutyric acid; HEK, human embryonic kidney; AChBP, acetylcholine binding protein; 5HTBP, an AChBP mutant modified to resemble the 5-HT₃R binding site; VUF10166, 2-chloro-3-(4-methylpiperazin-1-yl)quinoxaline.

* Corresponding author. Tel.: +44 (0) 1223 765949; fax: +44 (0) 1223 333345.

E-mail address: sl120@cam.ac.uk (S.C.R. Lummis).




Fig. 1. Radioligand binding at 5-HT₃A receptors. (a) Representative binding curves for 5-HT₃A receptors. *Inset* competition binding of unlabelled VUF10166 with [³H]granisetron. (b) Association of [³H]VUF10166 was fit with a mono-exponential function to yield k_{obs} . (c) Linear regression was used to fit k_{obs} against the radioligand concentration, yielding the k_{on} (slope) and k_{off} (intercept at $y = 0$) values in Table 1. (d) Dissociation of [³H]VUF10166 was best fit with a single exponential ($k_{off} = 0.011 \pm 0.001 \text{ min}^{-1}$, $n = 4$). (e) For [³H]granisetron, association was also best fit with mono-exponential functions that were used to plot k_{obs} against the concentration to yield the k_{on} and k_{off} values in Table 1. (f) Dissociation of [³H]granisetron ($k_{off} = 0.011 \pm 0.001 \text{ min}^{-1}$, $n = 5$).

and also target other receptor types. More recently there have been descriptions of two compounds with other sites of action that discriminate between 5-HT₃A and 5-HT₃AB receptor subtypes. One of these, toptecan, primarily an anticancer drug, was found to inhibit 5-HT₃A and potentiate 5-HT₃AB receptors, although this compound also has a relatively low (μM) potency (Nakamura et al., 2013). The second compound is VUF10166 (2-chloro-3-(4-methylpiperazin-1-yl)quinoxaline), which is highly potent, with an affinity at 5-HT₃A receptors ($pK_i \sim 10$) that is ~ 100 -fold greater than at 5-HT₃AB receptors (Thompson et al., 2012). We previously showed that VUF10166 binds to the orthosteric binding site of both 5-HT₃A and 5-HT₃AB receptors (formed at the interface of two 5-HT₃A subunits, A+A-) and that a second, allosteric, binding site

(A+B-) in the 5-HT₃AB receptor was responsible for causing ligands at the A+A- binding site to dissociate more rapidly.

Here we perform a detailed characterisation of VUF10166 binding to 5-HT₃A and 5-HT₃AB receptors with a radiolabelled version of this compound and use mutagenesis to explore the residues that interact with VUF10166 at the A+A- binding site.

2. Experimental procedures

2.1. Synthesis of [³H]VUF10166

60 μl [³H]methyl nosylate (0.7 GBq/ml, 19 mCi/ml) in hexane/ethyl acetate (10/2 v/v) was injected into a closed reaction screwcap reaction vessel and the solvent evaporated under argon at 60 °C. 2-chloro-3-(piperazin-1-yl)quinoxaline hydrochloride (7.2 mg, 0.025 mmol) in dry DMF (150 μl) and DIPEA (30.7 μl , 0.176 mmol)

were added for 1 h at room temperature. The reaction was quenched with 500 μ l semi-prep HPLC eluent and subjected to semi-preparative HPLC purification, using a Reprosphere C18-DE 5 μ m, 50 \times 8 mm column as stationary phase (Dr. Maisch, Ammerbuch-Entringen, Germany) and acetonitrile/water 75/25 (v/v) with 0.1% diisopropylethylamine as eluent at a flow of 3 ml min⁻¹, with UV monitoring at 254 nm (Jasco UV-1575, Jasco, de Meern, Netherlands). 30 s fractions were collected, 5 μ l of each added to 5 ml scintillation fluid, and counted for 1 min in a beta well counter (Rackbeta 1219 LSC, LKB-Wallac, Netherlands). Fractions containing 2-chloro-3-(4-[³H]methylpiperazin-1-yl)quinoxaline were diluted with 45 ml sterile water and passed over a preconditioned Waters tC18 plus Sep-Pak, washed with 20 ml of water, and the product obtained by elution with 1.5 ml ethanol; 35 MBq (83% radiochemical yield) of [³H]VUF10166 was obtained. The specific activity of the product was 3.13 TBq/mmol (84.5 Ci/mmol) and the radiochemical purity was >98%, as determined by HPLC with a Platinum C18 100a, 5 μ m 250 \times 4.6 mm column (Grace Alltech, Breda, Netherlands) as stationary phase and acetonitrile/10 mM ammoniumdihydrogen phosphate buffer pH 2.5 50/50 (v/v) as eluent at a flow of 1 ml min⁻¹, with UV monitoring at 254 nm (Jasco UV-1575) and radioactivity monitoring (Lablogic β -RAM model 4, Metorix, Goedereede, Netherlands).

2.2. Site-directed mutagenesis

Mutagenesis was performed using the QuikChange method (Agilent Technologies Inc., California, USA) on human 5-HT_{3A} cDNA (accession number: P46098) cloned into pcDNA3.1 (Invitrogen, Paisley, UK). Cysteine residues were substituted for amino acids throughout each of the binding loops A–E (Fig. 1). To facilitate comparisons with previous work, we use the numbering of the equivalent residues in the mouse 5-HT_{3A} subunit; for human numbering 5 should be subtracted from each residue number.

2.3. Cell culture and transfection

Human embryonic kidney (HEK) 293 cells were maintained as monolayer cultures grown on 90 mm tissue culture plates in DMEM:F12 (Dulbecco's Modified Eagle Medium/Nutrient Mix F12 (1:1)) with GlutaMAX™ I media (Gibco BRL, Paisley, U.K.) containing 10% foetal calf serum (HyClone, Thermo Scientific, Cramlington, UK), at 37 °C and 7% CO₂, with a humidified atmosphere. Cells were transfected using polyethylenimine (PEI, Polysciences Inc., Eppelheim, Germany), and incubated for 2–3 days before harvesting.

2.4. Radioligand binding

Transfected HEK 293 cells were washed twice with phosphate buffered saline (PBS) at room temperature, scraped into 1 ml of ice-cold HEPES buffer (10 mM, pH 7.4), homogenised and frozen. After thawing, they were washed with HEPES buffer, resuspended, and 50 μ g of cell suspension incubated in 0.5 ml HEPES buffer and the relevant concentration of radioligand at 0 °C. Non-specific binding was determined using 2 mM quipazine. Equilibrium reactions were incubated for at least 3 h for [³H]granisetron (63.5 Ci/mmol, PerkinElmer, Boston, Massachusetts, USA) and 48 h for [³H]VUF10166. Incubations were terminated by vacuum filtration onto GF/B filters pre-soaked in 0.3% polyethyleneimine, followed by three rapid washes with 3.5 ml ice cold buffer. Radioactivity was determined by scintillation in Ecosint A (National Diagnostics, Atlanta, Georgia) using a Beckman LS6000SC (Fullerton, California, USA). Each method was performed on at least three independent cell samples on at least three separate days.

2.4.1. Saturation binding

To construct saturation binding curves a range of [³H]granisetron (0.25–2 nM) or [³H]VUF10166 (0.04–50 nM) concentrations were used according to the conditions described above. Final counts were monitored to ensure that binding never exceeded 10% of the added concentrations of radioligands.

2.4.2. Competition binding

Affinities of unlabelled Cys-loop receptor ligands were determined by adding a range (2 pM–2 mM) of concentrations to samples containing 0.2 nM [³H]VUF10166 or 0.7 nM [³H]granisetron for 5-HT_{3A} receptors, and 0.6 nM [³H]VUF10166 or 0.7 nM [³H]granisetron for 5-HT_{3AB} receptors.

2.4.3. Kinetic measurements

To determine the association rate (k_{on}), the observed association rate (k_{obs}) was measured for a range of radioligand concentrations. The experiment was started ($t = 0$) by the addition of radioligand to 500 μ l cell suspension in HEPES buffer and harvested at varying time points to construct association curves.

Dissociation was measured by allowing each radioligand to reach equilibrium according to the times described above and then adding a final concentration of 2 mM quipazine ($-K_d \times 10^6$) to each tube for varying time periods.

2.5. Data analysis

All data were analysed using GraphPad Prism 4.03. Individual saturation binding experiments were fitted to Equ (1), and the values averaged to obtain mean \pm sem:

Table 1
Binding parameters for VUF10166 and BRL43694.

Receptor	k_{on} (M ⁻¹ min ⁻¹)	k_{off} (min ⁻¹)	K_d (nM) (k_{on}/k_{off})	K_d (nM) saturation	K_i (nM) competition ^a
VUF10166					
5-HT _{3A}	6.25×10^7	0.010	0.16	0.18 ± 0.04 (11)	0.24 ± 0.11 (12)
5-HT _{3AB}	^b 6.15×10^7 ^b 7.23×10^6	0.024 0.162	0.38 22.4	–	36.7 ± 12.4 (12)
BRL43694					
5-HT _{3A}	5.90×10^7	0.064	1.08	0.68 ± 0.05 (12)	–
5-HT _{3AB}	1.20×10^8	0.074	0.62	0.74 ± 0.10 (4)	–

^a Competition binding was performed with [³H]BRL43694 and unlabelled VUF10166. k_{on} and k_{off} were calculated from plots of k_{obs} versus ligand concentration (Figs. 1 and 5). – not determined.

^b Not significantly different to 5-HT_{3A} ($p > 0.05$, Student's *t*-test).

$$y = B_{max} \times \left[\frac{L}{K_d + [L]} \right] \quad (1)$$

where B_{max} is maximum binding at equilibrium, K_d is the equilibrium dissociation constant and $[L]$ is the free concentration of radioligand. Individual competition binding experiments were analysed by iterative curve fitting using the following equation and the values averaged to obtain the mean \pm sem:

$$y = B_{min} + \frac{B_{max} - B_{min}}{1 + 10^{[L] \cdot \log IC_{50}}} \quad (2)$$

where B_{min} is the non-specific binding, B_{max} is the maximum specific binding, $[L]$ is the concentration of competing ligand and IC_{50} is the concentration of competing ligand that blocks half of the specific bound radioligand.

A simple bimolecular binding scheme for receptor and ligand can be represented as:



where L is the free ligand concentration, R receptor concentration, LR bound receptor concentration, and k_{on} and k_{off} microscopic association and dissociation rate constants. In a simple scheme such as this, the equilibrium dissociation constant (K_d) is equal to the ratio of dissociation to association rate constants, such that:

$$K_d = \frac{k_{off}}{k_{on}} \quad (4)$$

Dissociation data were fitted to either a single or double exponential decay to yield k_{off} . Association data were fitted to a single exponential association to calculate k_{obs} . If k_{obs} is plotted against the radioligand concentration, according to a simple model, the slope of this plot equals the association constant (k_{on}) and the y-intercept of this line (at $x = 0$) is the dissociation constant (k_{off}). k_{on} can also be calculated as described by Hill (Hill, 1909), where k_{off} is predetermined from radioligand dissociation rate experiments.

$$k_{on} = \frac{k_{obs} - k_{off}}{[L]} \quad (5)$$

2.6. Homology modelling

The protein sequence of the human 5-HT_{3A} subunit (accession number; P46098) was aligned with a tropisetron bound AChBP template (PDB ID; 2WNC) using FUGUE. Using Modeller 9.9, five homology models were generated using default parameters and the best model selected using Ramachandran plot analysis. For the ligand, the protonated form of VUF10166 was constructed in Chem3D Ultra 7.0 (CambridgeSoft, Cambridge, UK). The binding site was defined as being within 5 Å of the α -carbon of W183, a residue critical in the binding of other 5-HT₃ competitive ligands. VUF10166 was docked into this site using the GOLD docking program (version 3.0, The Cambridge Crystallographic Data Centre, Cambridge, UK) with the GOLDScore function and default settings. Ten docking poses were generated for each of the five homology models and the poses visualised with PyMol v1.3.

3. Results

3.1. [³H]VUF10166 binding at 5-HT_{3A} receptors

[³H]VUF10166 showed high affinity saturable binding at 5-HT_{3A} receptors with low levels (<5%) of non-specific binding. The K_d value was similar to the K_i value from competition of unlabelled

VUF10166 with [³H]granisetron (Fig. 1a, Table 1). B_{\max} values for [³H]VUF10166 (2229 ± 158 fmol/mg, $n = 6$) were comparable to those with [³H]granisetron (2263 ± 101 , $n = 6$) on paired samples, suggesting that both ligands bind to the same receptor population.

3.2. VUF10166 kinetic parameters at 5-HT₃A receptors

Association curves for [³H]VUF10166 were best fit with a single exponential function (Fig. 1b), and the resultant rates (k_{obs}) plotted against ligand concentration to yield k_{on} and k_{off} (Fig. 1c, Table 1). The value for k_{on} was similar to values determined directly from k_{obs} values using Equ (5) (8.24×10^7 M min⁻¹). Dissociation of [³H]VUF10166 in the presence of excess cold quipazine was also monophasic (Fig. 1d), with k_{off} values that were similar to those determined from plots of k_{obs} against ligand concentration (Table 1). K_d values calculated from these kinetic measurements (Equ (4)) were similar to those derived from the saturation and competition binding (Table 1). These results indicate [³H]VUF10166 binding can be best described by a simple bi-molecular binding scheme.

3.3. Specificity of binding

A range of competitive and non-competitive ligands of 5-HT₃ and related Cys-loop receptors were tested for their ability to compete with [³H]VUF10166 binding (Table 2). All tested 5-HT₃ receptor competitive ligands (agonists and antagonists) displaced specific [³H]VUF10166 binding. Binding was unaffected by the non-competitive ligands bilobalide, ginkgolide and picrotoxin, or the majority of competitive ligands of other Cys-loop receptors. Exceptions were strychnine (glycine receptor antagonist) and nicotine (nACh receptor agonist); these were later shown to also compete with [³H]granisetron.

Previously we showed that unlabelled VUF10166 does not compete with [³H]epibatidine at $\alpha 7$ nACh receptors (the closest pharmacologically related receptor) (Thompson et al., 2012). Here we performed saturation binding experiments on $\alpha 7$ nACh receptors using [³H]VUF10166 which revealed no specific saturable binding (data not shown).

These results show that classical 5-HT₃ receptor competitive antagonists compete with [³H]VUF10166, showing it binds at the orthosteric site.

Table 2
Competition of Cys-loop receptor ligands with [³H]VUF10166.

Compound	$pI_{C_{50}}$	
	5-HT ₃ A	5-HT ₃ AB
Allosetron	11.14 ± 0.01 (4)	11.15 ± 0.10 (4)
Quipazine	8.84 ± 0.03 (4)	8.60 ± 0.75 (5)
MDL72222	12.90 ± 0.01 (3)	13.23 ± 0.11(1)
mCPBG	7.49 ± 0.06 (4)	6.07 ± 0.20 (5)
Granisetron	10.48 ± 0.08 (4)	10.35 ± 0.10 (3)
d-Tubocurarine	5.41 ± 0.06 (4)	5.44 ± 0.30 (4)
5-HT	4.54 ± 0.07 (3)	4.49 ± 0.09 (3)
ACh	NB (4)	NB (3)
GABA	NB (4)	NB (3)
Glycine	NB (4)	NB (3)
Gabazine	NB (4)	NB (3)
Bicuculline	NB (5)	NB (3)
Strychnine	5.83 ± 0.09 (4)	6.26 ± 0.01 (2)
Picrotoxin	NB (3)	NB (3)
Bilobalide	NB (3)	NB (2)
Ginkgolide	NB (3)	NB (3)
Nicotine	6.81 ± 0.23 (4)	6.76 ± 0.09 (2)

3.4. Granisetron binding at 5-HT₃A receptors

To compare [³H]VUF10166 with a well-established 5-HT₃ receptor competitive ligand, experiments were also conducted using [³H]granisetron. As expected, [³H]granisetron showed high affinity binding at 5-HT₃A receptors (Table 1). Competition binding with a range of known 5-HT₃ receptor agonists and antagonists gave K_i values similar to those determined using competition with [³H]VUF10166 (Table 3) and to those published elsewhere (Brady et al., 2001). Similar to [³H]VUF10166, nicotine and strychnine competed with [³H]granisetron.

[³H]granisetron association rates were best fit with a monophasic curve. k_{obs} increased with free ligand concentration and a straight line was fitted (Fig. 1e) to yield the k_{on} and k_{off} values in Table 1. K_d values calculated from these kinetic measurements (Equ (4)) were in agreement with affinities calculated from our saturation binding studies (Table 1). Dissociation was also monophasic and the rate agreed well with that from our k_{obs} versus concentration plots described above (Fig. 1f, Table 1).

These observations show that using a well-established radiolabelled 5-HT₃ receptor antagonist ([³H]granisetron) we are able to accurately reproduce the binding characteristics reported elsewhere and, similar to [³H]VUF10166, they are consistent with a simple bi-molecular binding scheme.

3.5. Homology modelling & docking

To gain insights into the residues that potentially interact with VUF10166 at the orthosteric site (A+A- interface), five 5-HT₃A receptor homology models were generated and *in silico* docking of VUF10166 performed on each one (Fig. 2). A total of 50 docked poses were generated and for each of these the amino acids within 5 Å of VUF10166 were identified (Table 4). 26% of residues were common to all models, comparable to a previous docking study with granisetron, where 31% of residues were common to all of the predicted binding orientations (Thompson et al., 2005). A selection of these residues were chosen for mutagenesis based upon the following criteria, 1) side chains accessible to the ligand, 2) residues known to interact with other 5-HT₃ ligands or, 3) residues present in a limited number of docked poses to provide support for specific orientations. Of the 39 amino acids identified, 23 were mutated to cysteine (Fig. 3); cysteine substitution of these residues was chosen as all of the Cys mutants have been previously shown to express on the cell-surface, and the residue positions have been similarly used for the study of our radioligand standard, [³H]granisetron (Thompson et al., 2005, 2011).

3.6. Effects of mutations

The binding affinity of [³H]VUF10166 at each of the mutant receptors is shown in Table 5, and their locations in Fig. 4. Changing 3 of the 23 residues resulted in no significant change in affinity,

Table 3
Competition of Cys-loop receptor ligands with [³H]BRL43694.

Compound	$pI_{C_{50}}$	
	5-HT ₃ A	5-HT ₃ AB
Quipazine	8.60 ± 0.02 (5)	8.12 ± 0.18 (5)
MDL72222	8.05 ± 0.09 (3)	7.96 ± 0.15 (3)
mCPBG	6.88 ± 0.13 (7)	6.64 ± 0.12 (5)
Granisetron	9.12 ± 0.05 (7)	9.14 ± 0.09 (4)
d-Tubocurarine	4.61 ± 0.17 (3)	4.29 ± 0.47 (3)
5-HT	6.38 ± 0.35 (6)	5.64 ± 0.45 (5)
Nicotine	6.01 ± 0.61 (3)	6.56 ± 0.12 (3)
Strychnine	4.30 ± 0.09 (3)	4.85 ± 0.19 (3)




Fig. 2. Predicted binding clusters for VUF10166 docked into five different homology models of the 5-HT₃ receptor A+A⁻ binding site. All 10 predicted ligand poses are shown for each model. The 5-HT₃ receptor residues within 5 Å of VUF10166 in each of the docked poses are shown in [Table 4](#).

suggesting these residues do not play a role in ligand binding (I71, K112, S114). For the remaining 20 mutants there were differences in the binding affinities when compared to wild type receptors, indicating that these residues may have a role in VUF10166 binding. For 9 of these residues [³H]VUF10166 had reduced affinities (R92, L126, N128, I139, R145, Q151, Y153, H185, F226) and for 11 no saturable binding ($K_d > 10$ nM) was detected (R58, W90, E129, Y141, Y143, T179, T181, W183, H185, D189, Y234, E236). All these mutant receptors have been previously shown to express in oocytes ([Thompson et al., 2012](#)).

These data show that [³H]VUF10166 binds to the orthosteric site and are consistent with our findings that [³H]VUF10166 competes with other 5-HT₃ receptor competitive ligands.

3.7. VUF10166 binding at 5-HT_{3AB} receptors

VUF10166 was previously shown to discriminate between 5-HT₃ receptors subtypes ([Thompson et al., 2012](#)) and so binding properties of the new radioligand were also tested at 5-HT_{3AB} receptors. [³H]VUF10166 showed high affinity binding at 5-

Table 5
Saturation binding of [³H]VUF10166 at 5-HT₃A receptor mutants.

Alanine Mutant	K_d (nM) Mean ± SEM	n	Fold change	K_d (nM)			
				0	1	2	3
Wild Type	0.21 ± 0.04	13	-	0	1	2	3
* R58C	NB	4	-				
I71C	0.23 ± 0.05	4	1.1				
Loop D	* W90C	NB	-				
	* R92C	0.88 ± 0.19	5	4.2			
	K112C	0.13 ± 0.03	3	1.6			
	S114C	0.21 ± 0.09	3	1.0			
Loop A	* L126C	0.89 ± 0.19	8	4.2			
	N128C	0.70 ± 0.10	4	3.3			
	* E129C	NB	7	-			
Loop E	* I139C	1.55 ± 0.15	3	7.4			
	* Y141C	NB	6	-			
	* Y143C	NB	9	-			
	R145C	0.96 ± 0.35	3	4.6			
	* Q151C	1.82 ± 0.19	4	8.7			
	* Y153C	2.03 ± 0.33	5	9.7			
Loop B	* T179C	NB	5	-			
	* T181C	NB	7	-			
	* W183C	NB	6	-			
	* H185C	0.96 ± 0.39	5	4.5			
	* D189C	NB	7	-			
Loop C	* F226C	1.59 ± 0.08	3	7.6			
	* N232C	1.90 ± 0.36	5	9.0			
	* Y234C	NB	6	-			
* E236C	NB	3	-				

* Significantly different to wild type ($p > 0.05$, Student's T-test).

These results show that [³H]VUF10166 has different binding properties at 5-HT₃A and 5-HT₃AB receptors. In the latter effects are complex and some only become apparent at higher concentrations of [³H]VUF10166.

3.8. Granisetron binding at 5-HT₃AB receptors

Unlike [³H]VUF10166, [³H]granisetron saturation binding at 5-HT₃AB receptors yielded K_d values that were the same as those at 5-HT₃A receptors, as reported elsewhere (Table 1) (Brady et al., 2001). Association (Fig. 5e), dissociation (Fig. 5f) and K_i values from competition binding (Table 3) were also the same as those at 5-HT₃A receptors.

These results show that the binding properties of [³H]granisetron are the same at 5-HT₃A and 5-HT₃AB receptors unlike those of [³H]VUF10166.

4. Discussion

[³H]VUF10166 binds specifically and with high affinity to 5-HT₃A and 5-HT₃AB receptors, with evidence of a second, lower affinity, binding site in 5-HT₃AB receptors. The effects of this second site are apparent at concentrations of [³H]VUF10166 > 3 nM, and are consistent with previous work that identified an additional allosteric binding site for unlabelled VUF10166 at the A+B- interface (Thompson et al., 2012). Docking of this competitive ligand into the orthosteric (A+A-) binding site, combined with data from mutagenesis, suggest that VUF10166 is oriented with its quinoxaline rings close to W183 and its basic nitrogen extended towards loop E. Individual residues, many of which have been previously shown to be important in studies of other 5-HT₃ receptor ligands (including *d*-tubocurarine, granisetron, lerisetron, *meta*-chlorophenylbiguanide and tropisetron) are also important for VUF10166 binding (Hope et al., 1999; Mochizuki et al., 1999;




Fig. 4. Binding site residues mutated in this study, colour coded according to the change in K_d . A large number of residues that abolish binding (affinity > 10 nM) are clustered around loop B, with further significant changes in loop D (W90) and loop E (Y141 & Y143). Not all changes are likely to result from ligand interactions, such as the effect of D189C which is consistent with it maintaining the hydrogen bond network in the tight loop at the C-terminal end of loop B. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Venkataraman et al., 2002a; Price and Lummis, 2004). The residues are discussed in more detail below.

4.1. The role of loop A residues

VUF10166 binding was abolished by Cys substitution of E129, slightly modified by L126C (−4 fold change in K_d) and not altered by N128C. E129 was previously identified as an important 5-HT₃ receptor binding residue and may form a hydrogen bond with bound ligand, which is consistent with our data (Price et al., 2008). However, data from 5HTBP (a modified AChBP with high affinity binding for 5-HT₃ receptor ligands) suggest that E129 may hydrogen bond with the side chain of T179 (Kesters et al., 2013), and therefore might have primarily a structural role. L126 may also have a structural role but is less important as the effects of altering this residue were small, while N128 has been shown to play a role in gating but not binding (Price et al., 2008; Kesters et al., 2013).

4.2. The role of loop B residues

Loop B has been previously identified as both a critical structural component of the binding pocket, and it contributes to ligand binding. W183 is especially important as a constituent of the ‘aromatic box’ that exists in all Cys-loop receptor binding sites (Beene et al., 2002; Thompson et al., 2008b; Duffy et al., 2012). Other residues (T179, H185, D189) are known to stabilise the binding site structure via hydrogen bonds (Thompson et al., 2008b; Kesters et al., 2013). It is therefore not surprising that all our loop B mutations altered or abolished [³H]VUF10166 binding and we suggest that T181 and W183 interact with VUF10166 while T179, H185 and D189 have a structural role.

4.3. The role of loop C residues

F226 and Y234 are also constituents of the aromatic box and mutations here alter or eliminate VUF10166 binding. F226A has no effect on granisetron binding affinity, indicating this residue is more important for VUF10166 binding (Thompson et al., 2005). In 5HTBP Y234 (Y193) interacts with 5-HT and also contributes to a conserved water network that stabilises the granisetron-bound structure (Kesters et al., 2013); a conserved water network is also seen at this location in many AChBP crystal structures and may be

important in many Cys-loop receptors. E236C also abolished VUF10166 binding, consistent with studies where substitutions affect binding of both GR65630 and granisetron, as well as altering the maximal current and EC_{50} of 5-HT responses (Schreiter et al., 2003; Nyce et al., 2010). However E236 mutations may adversely affect the correct assembly of the binding site rather than interfering with specific ligand interactions as Nyce et al. (2010) and Schreiter et al. (2003) showed that some E236 mutant receptors are trapped within the cell. As this hypothesis is supported by the lack of interactions in the 5HTBP structure, we consider it unlikely that E236 contributes to VUF10166 binding (Kesters et al., 2013).

4.4. The role of loop D residues

W90 is another aromatic box residue that contributes to binding. In 5HTBP the equivalent residue (W53) is involved in van der Waals interactions with granisetron and W90 may have a similar role in binding VUF10166 (Spier and Lummis, 2000; Price and Lummis, 2004; Thompson et al., 2005; Yan and White, 2005). Substitutions at W90 decrease the affinity of other potent 5-HT₃ receptor-specific ligands such as curare, lerisetron and 5-HT (Yan et al., 1999; Venkataraman et al., 2002a) R92 interacts with granisetron in 5HTBP (R55), and the effects of its substitution on the affinity of VUF10166, ondansetron, granisetron and MDL72222, suggest an interaction with all of these ligands (Thompson et al., 2005; Yan and White, 2005).

4.5. The role of loop E residues

All of the mutations in loop E (Y141, Y143, R145, Q151, Y153) caused significant changes to [³H]VUF10166 binding. In the 5HTBP crystal structure granisetron does not extend towards loop E, but instead lies horizontally between loops B and D, similar to the orientations of the closely related ligands tropisetron (2WNC) and cocaine (2PGZ) in AChBP. In contrast, in 5HTBP 5-HT hydrogen bonds with the backbone carbonyls of I104 (Y141 in 5-HT₃) and I116 (Y153), and has hydrophobic interactions with M114 (Q151), explaining why 5-HT activation is strongly affected by mutations at these locations, but effects on granisetron are less apparent (Venkataraman et al., 2002b; Price and Lummis, 2004; Thompson et al., 2011; Kesters et al., 2013). Here the affinity of VUF10166 was decreased 10-fold by Y153C and abolished by Y143C, indicating




Fig. 5. Radioligand binding at 5-HT₃AB receptors. (a) Binding at 5-HT₃AB receptors could not be well fit with a standard one site model; deviation occurs at a radioligand concentration of ~3 nM (arrow). *Inset* competition binding of unlabelled VUF10166 with [³H]granisetron. (b) Dissociation was best fit with a double exponential at 5-HT₃AB receptors ($0.010 \pm 0.003 \text{ min}^{-1}$ and $0.227 \pm 0.056 \text{ min}^{-1}$, $n = 8$). (c) Association was mono-exponential, but a plot of k_{obs} against radioligand concentration, (d) revealed two components, showing that it was rate-limited at higher concentrations. (e) The association of [³H]granisetron was best fit with a mono-exponential function, but unlike [³H]VUF10166, the fit of k_{obs} against the radioligand concentration was linear at across all concentrations, yielding the values for k_{on} and k_{off} in Table 1. (f) Consistent with this plot, dissociation of [³H]granisetron was also best described by a single exponential function ($k_{\text{off}} = (0.012 \pm 0.002 \text{ min}^{-1})$, $n = 5$) that was not significantly different to 5-HT₃A receptors ($p > 0.05$, Student's *t*-test).

that bound VUF10166 extends towards, and may interact with, loop E residues. As VUF10166 is also a low efficacy partial agonist at μM concentrations, and must therefore induce the same structural changes as 5-HT, it is likely it adopts an orientation that at least partially mimics that of 5-HT.

4.6. The orientation of VUF10166 in the ligand binding pocket

Our results show that VUF10166 binding is affected by many of the residues previously identified as important for binding 5-HT₃

receptor antagonists, while mutation of R58, I71, K112 and S114, which are close to VUF10166 in models 1, 2 and 5, did not alter its affinity, suggesting that these models are less probable. Also in model 1 the predicted ligand orientations do not extend towards Loop E and yet residues here were important for VUF10166 binding. Similarly R145 is within 5 Å of VUF10166 in model 2, but our mutagenesis data show that altering this residue has little effect on binding affinity. Model 3 seems unlikely as these poses are positioned closer to the complimentary face of the binding site, and do not significantly interact with key principal face residues such as




Fig. 6. Chemical structure of VUF10166 and its binding mode. (a) Three regions of the ligand are identified and are described in the text. Its protonation site, which is also its tritiation site, is indicated. (b–c) The volume occupied by the two main docked pose clusters in model 4. In (c) cation– π interactions are possible with W183 (5.06 Å away) and Y234 (4.46 Å). VUF10166 is shown as a stick and wire mesh representation (white), with the residues mutated in this study colour coded similar to Fig. 4. (d–e) Cartoons showing our interpretation of the binding to heteromeric receptors. Below 3 nM, VUF10166 binds to a single population of binding sites at the A+A– interface of both 5-HT₃A and 5-HT₃AB receptors; consequently, at these concentrations both receptors share common values for k_{on} and k_{off} . At concentrations of VUF10166 > 3 nM, binding also occurs at a second A+B– binding site and allosterically influences the adjacent A+A– site; therefore, additional rates are apparent and saturation binding is confounded by rates associated with multiple binding sites and allosteric interactions. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

T181, W183 and Y234. Models 4 and 5 have quite similar docked poses with only F226 distinguishing them; F226C mutant receptors had a 7-fold lower affinity than wild type receptors suggesting that this residue is close enough to interfere with VUF10166 binding, which would best fit with model 4.

In previous work we presented a structure-activity study (SAR) of VUF10166 analogues (Verheij et al., 2012; Thompson et al., 2013) and the active analogues from these studies would fit well into model 4 in two distinct orientations (Fig. 6). These data showed substitutions of the chlorine atom in VUF10166 (Fig. 6a, region 2) are poorly tolerated, suggesting an important interaction at this

location; in both poses in Fig. 6 the chlorine atom is closely located to R92 and W90. In contrast, substitutions in regions 1 and 3 are fairly well tolerated, providing that they are not too large; neither of the poses in Fig. 6 are sterically restricted around these regions of VUF10166. The poses also explain the importance of the charged N-methylpiperazine nitrogen atom, as there are possible cation– π interactions with W183 and Y234 in one pose, with these residues contributing to π – π stacking of the quinoxaline ring in the other.

We therefore suggest that the docked poses in model 4 are most consistent with the mutagenesis data described here and our previously published SAR. It is difficult to predict whether the N-

methylpiperazine ring or the quinoxaline ring is positioned toward loop E, but the orientation in Fig. 6c is most reminiscent of varenicline co-crystallised into AChBP (PDBID = 4AFG & 4AFT) and 5-HT in 5HTBP (2YMD), both of which are agonists at 5-HT₃ receptors (Billen et al., 2012; Rucktooa et al., 2012). This similarity in orientation may explain why VUF10166 also displays partial agonist activity (Thompson et al., 2012). However, it should be stressed that we must exercise caution when making these predictions as the physiological relevance of these structures have not yet been fully ascertained, for example three ligand molecules have been observed in a single AChBP binding site, something we would not have predicted (Brams et al., 2011; Stornaiuolo et al., 2013).

5. Conclusion

Our results show that VUF10166 interacts with several of the core binding site residues found at the A+A⁻ interface and, combined with homology modelling and ligand docking, we propose it adopts an orientation similar to that of other 5-HT₃ receptor agonists in AChBP and 5HTBP crystal structures. At 5-HT₃ receptors our kinetic measurements are consistent with a single A+A⁻ binding site, but at 5-HT₃AB an additional fast component is seen. This is consistent with the lower affinity of VUF10166 for the 5-HT₃AB receptor and is likely to result from an allosteric effect that is evident when the concentration of VUF10166 exceeds 3 nM (as summarised in Fig. 6).

Acknowledgements

We thank Linda Silvestri for her excellent technical assistance and Martin Lochner for his chemical insights. S.C.R.L. and I.d.E. would like to acknowledge an EEC FP7 grant (Neurocypres) for financial support. S.C.R.L. is a Wellcome Trust Senior Research Fellow in Basic Biomedical Studies (081925).

References

Beene, D.L., Brandt, G.S., Zhong, W., Zacharias, N.M., Lester, H.A., Dougherty, D.A., 2002. Cation- π interactions in ligand recognition by serotonergic (5-HT_{3A}) and nicotinic acetylcholine receptors: the anomalous binding properties of nicotine. *Biochemistry* 41, 10262–10269.

Billen, B., Spurny, R., Brams, M., van Elk, R., Valera-Kummer, S., Yakel, J.L., et al., 2012. Molecular actions of smoking cessation drugs at α 4 β 2 nicotinic receptors defined in crystal structures of a homologous binding protein. *Proc. Natl. Acad. Sci. U. S. A.* 109, 9173–9178.

Brady, C.A., Stanford, I.M., Ali, I., Lin, L., Williams, J.M., Dubin, A.E., et al., 2001. Pharmacological comparison of human homomeric 5-HT_{3A} receptors versus heteromeric 5-HT_{3A/3B} receptors. *Neuropharmacology* 41, 282–284.

Brams, M., Pandya, A., Kuzmin, D., van Elk, R., Krijnen, L., Yakel, J.L., et al., 2011. A structural and mutagenic blueprint for molecular recognition of strychnine and d-tubocurarine by different Cys-loop receptors. *PLoS Biol.* 9, e1001034.

Celie, P.H., van Rossum-Fikkert, S.E., van Dijk, W.J., Brejc, K., Smit, A.B., Sixma, T.K., 2004. Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. *Neuron* 41, 907–914.

Duffy, N.H., Lester, H.A., Dougherty, D.A., 2012. Ondansetron and granisetron binding orientation in the 5-HT₃ receptor determined by unnatural amino acid mutagenesis. *ACS Chem. Biol.* 7, 1738–1745.

Hill, A.V., 1909. The mode of action of nicotine and curari, determined by the form of the contraction curve and the method of temperature coefficients. *J. Physiol.* 39, 361–373.

Holbrook, J.D., Gill, C.H., Zebda, N., Spencer, J.P., Leyland, R., Rance, K.H., et al., 2009. Characterisation of 5-HT_{3C}, 5-HT_{3D} and 5-HT_{3E} receptor subunits: evolution, distribution and function. *J. Neurochem.* 108, 384–396.

Hope, A.G., Belelli, D., Mair, I.D., Lambert, J.J., Peters, J.A., 1999. Molecular determinants of (+)-tubocurarine binding at recombinant 5-hydroxytryptamine_{3A} receptor subunits. *Mol. Pharmacol.* 55, 1037–1043.

Kesters, D., Thompson, A.J., Brams, M., van Elk, R., Spurny, R., Geitmann, M., et al., 2013. Structural basis of ligand recognition in 5-HT₃ receptors. *EMBO Rep.* 14, 49–56.

Miller, P.S., Smart, T.G., 2012. Binding, activation and modulation of Cys-loop receptors. *Trends Pharmacol. Sci.* 31, 161–174.

Mochizuki, S., Miyake, A., Furuichi, K., 1999. Identification of a domain affecting agonist potency of meta-chlorophenylbiguanide in 5-HT₃ receptors. *Eur. J. Pharmacol.* 369, 125–132.

Nakamura, Y., Ishida, Y., Yamada, T., Kondo, M., Shimada, S., 2013. Subunit-dependent inhibition and potentiation of 5-HT₃ receptor by the anticancer drug, topotecan. *J. Neurochem.* 125, 7–15.

Nyce, H.L., Stober, S.T., Abrams, C.F., White, M.M., 2010. Mapping spatial relationships between residues in the ligand-binding domain of the 5-HT₃ receptor using a molecular ruler. *Biophys. J.* 98, 1847–1855.

Price, K.L., Bower, K.S., Thompson, A.J., Lester, H.A., Dougherty, D.A., Lummis, S.C., 2008. A hydrogen bond in loop A is critical for the binding and function of the 5-HT₃ receptor. *Biochemistry* 47, 6370–6377.

Price, K.L., Lummis, S.C., 2004. The role of tyrosine residues in the extracellular domain of the 5-hydroxytryptamine₃ receptor. *J. Biol. Chem.* 279, 23294–23301.

Rucktooa, P., Haseler, C.A., van Elk, R., Smit, A.B., Gallagher, T., Sixma, T.K., 2012. Structural characterization of binding mode of smoking cessation drugs to nicotinic acetylcholine receptors through study of ligand complexes with acetylcholine-binding protein. *J. Biol. Chem.* 287, 23283–23293.

Schreier, C., Hovius, R., Costioli, M., Pick, H., Kellenberger, S., Schild, L., et al., 2003. Characterization of the ligand-binding site of the serotonin 5-HT₃ receptor: the role of glutamate residues 97, 224 and 235. *J. Biol. Chem.* 278, 22709–22716.

Spier, A.D., Lummis, S.C., 2000. The role of tryptophan residues in the 5-Hydroxytryptamine₃ receptor ligand binding domain. *J. Biol. Chem.* 275, 5620–5625.

Stornaiuolo, M., De Kloe, G.E., Rucktooa, P., Fish, A., van Elk, R., Edink, E.S., et al., 2013. Assembly of a π - π stack of ligands in the binding site of an acetylcholine-binding protein. *Nat. Commun.* 4, 1875.

Thompson, A.J., 2013. Recent developments in 5-HT₃ receptor pharmacology. *Trends Pharmacol. Sci.* 34, 100–109.

Thompson, A.J., Lester, H.A., Lummis, S.C.R.L., 2008a. The structural basis of function in Cys-loop receptors. *Q. Rev. Biophys.* 43, 449–499.

Thompson, A.J., Lochner, M., Lummis, S.C., 2008b. Loop B is a major structural component of the 5-HT₃ receptor. *Biophys. J.* 95, 5728–5736.

Thompson, A.J., Lummis, S.C., 2013. Discriminating between 5-HT_{3A} and 5-HT_{3AB} receptors. *Br. J. Pharmacol.* 169, 736–747.

Thompson, A.J., Lummis, S.C.R., 2007. The 5-HT₃ receptor as a therapeutic target. *Expert Opin. Ther. Targ.* 11, 527–540.

Thompson, A.J., Price, K.L., Lummis, S.C., 2011. Cysteine modification reveals which subunits form the ligand binding site in human heteromeric 5-HT₃AB receptors. *J. Physiol.* 589, 4243–4257.

Thompson, A.J., Price, K.L., Reeves, D.C., Chan, S.L., Chau, P.L., Lummis, S.C., 2005. Locating an antagonist in the 5-HT₃ receptor binding site using modeling and radioligand binding. *J. Biol. Chem.* 280, 20476–20482.

Thompson, A.J., Verheij, M.H., de Esch, I.J., Lummis, S.C., 2012. VUF10166, a novel compound with differing activities at 5-HT_{3A} and 5-HT_{3AB} receptors. *J. Pharmacol. Exp. Ther.* 341, 350–359.

Thompson, A.J., Verheij, M.H., van Muijlwijk-Koejen, J.E., Lummis, S.C., Leurs, R., de Esch, I.J., 2013. Structure-activity relationships of quinoxaline-based 5-HT_{3A} and 5-HT_{3AB} receptor-selective ligands. *ChemMedChem* 8, 946–955.

Venkataraman, P., Joshi, P., Venkatachalan, S.P., Muthalagi, M., Parihar, H.S., Kirschbaum, K.S., et al., 2002a. Functional group interactions of a 5-HT_{3R} antagonist. *BMC Biochem.* 3, 16.

Venkataraman, P., Venkatachalan, S.P., Joshi, P.R., Muthalagi, M., Schulte, M.K., 2002b. Identification of critical residues in loop E in the 5-HT_{3ASR} binding site. *BMC Biochem.* 3, 15.

Verheij, M.H., Thompson, A.J., van Muijlwijk-Koejen, J.E., Lummis, S.C., Leurs, R., de Esch, I.J., 2012. Design, synthesis, and structure-activity relationships of highly potent 5-HT₃ receptor ligands. *J. Med. Chem.* 55, 8603–8614.

Walstab, J., Rappold, G., Niesler, B., 2010. 5-HT₃ receptors: role in disease and target of drugs. *Pharmacol. Ther.* 128, 146–169.

Yan, D., Schulte, M.K., Bloom, K.E., White, M.M., 1999. Structural features of the ligand-binding domain of the serotonin 5HT₃ receptor. *J. Biol. Chem.* 274, 5537–5541.

Yan, D., White, M.M., 2005. Spatial orientation of the antagonist granisetron in the ligand-binding site of the 5-HT₃ receptor. *Mol. Pharmacol.* 68, 365–371.